The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Open accessAbstract
BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This observation is therefore in accordance with recent clinical trials showing that antifibrotic therapies are effective in progressive fibrotic interstitial lung diseases other than IPF [20,26,27].”
In the citing paper
“nintedanib has also now been approved for systemic sclerosis (SSc)-associated ILD (SSc-ILD), based on the positive outcome of Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (Distler et al., 2019).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Distler et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationvan den Hoogen, F. H. J., Khanna, D., Fransen, J., Johnson, S. R., Baron, M. G., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,881
Self-citationThe St George's Respiratory Questionnaire
Jones, P., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,729
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial Lung Disease in Systemic Sclerosis
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J. C., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,249
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J. G., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,077
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C. P., Farge, D., Kowal‐Bielecka, O., Müller‐Ladner, U., Bocelli‐Tyndall, C., & Matucci‐Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 927
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,000
Yen, T., Tseng, C., Wang, K.-L., & Fu, P. (2021) · Medicina · doi:10.3390/medicina57121358 · Cited by 17
Kasugamycin Is a Novel Chitinase 1 Inhibitor with Strong Antifibrotic Effects on Pulmonary Fibrosis
Lee, J., Lee, C.-M., Lee, J. H., Kim, M.-O., Park, J. W., Kamle, S., Akosman, B., Herzog, E. L., Peng, X. Y., Elias, J. A., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0156oc · Cited by 17
Knarborg, M., Hyldgaard, C., Bendstrup, E. M., Davidsen, J. R., Løkke, A., Shaker, S. B., & Hilberg, O. (2022) · Chronic Respiratory Disease · doi:10.1177/14799731221125559 · Cited by 17
Pamrevlumab in idiopathic pulmonary fibrosis
Wells, A. U. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30339-x · Cited by 17
Derivation and Validation of a Diagnostic Prediction Tool for Interstitial Lung Disease
Pugashetti, J. V., Kitich, A., Alqalyoobi, S., Maynard-Paquette, A.-C., Pritchard, D., Graham, J., Boctor, N., Kulinich, A. G., LaFond, E., Foster, E. E., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.02.044 · Cited by 17
Fibrosis in Immune-Mediated and Autoimmune Disorders
Żurawek, M., Ziółkowska‐Suchanek, I., & Iżykowska, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186636 · Cited by 18
Komura, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691988 · Cited by 16
Fibroblasts as regulators of lung immunity, repair and fibrosis
Bell, P. T., & Belz, G. T. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01268-4 · Cited by 19
Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma
Torok, K. S. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.07.004 · Cited by 16
Lian, X., Ye, Y., Zou, J., Wu, C., Ye, S., Guo, Q., Chen, S., Lu, L., Wang, R., Fu, Q., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac525 · Cited by 16
Jang, H. J., Woo, A., Kim, S. Y., Yong, S. H., Park, Y., Chung, K. S., Lee, S. H., Leem, A. Y., Lee, S. H., Kim, E. Y., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2179659 · Cited by 16
Madsen, S. F., Sand, J. M. B., Juhl, P., Karsdal, M. A., Thudium, C. S., Siebuhr, A. S., & Bay‐Jensen, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-36416-6 · Cited by 19
Wortel, C. M., Liem, S. I. E., van Leeuwen, N. M., Boonstra, M., Fehres, C. M., Stöger, J. L., Huizinga, T. W. J., Toes, R. E. M., de Vries-Bouwstra, J. K., & Scherer, H. U. (2023) · RMD Open · doi:10.1136/rmdopen-2023-003148 · Cited by 16
Damiani, A., Orlandi, M., Bruni, C., Bandini, G., Lepri, G., Scaletti, C., Ravaglia, C., Frassanito, F., Guiducci, S., Pignone, A. M., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02725-1 · Cited by 16
Ross, L., Hansen, D., Proudman, S., Khanna, D., Herrick, A. L., Stevens, W., Baron, M. G., & Nikpour, M. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42939 · Cited by 16
2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis
Kayser, C., Delgado, S. M. D. O., Zimmermann, A. F., Horimoto, A. M. C., Rio, A. P. T. D., Müller, C. D. S., Camargo, C. Z., LUPO, C. M., Moraes, D. A., Souza, E. J. D. R. E., et al. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00392-w · Cited by 16
Systemic sclerosis: Advances towards stratified medicine
Quinlivan, A., Ross, L., & Proudman, S. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101469 · Cited by 16
Gayle, A., Schoof, N., Alves, M., Clarke, D. L., Raabe, C., Das, P., Galdo, F. D., & Maher, T. M. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01330-0 · Cited by 16
Self-citationConca, W., Weheba, I., Abouzied, M., Abdelsayed, A., Aleyouni, Y., Mutairy, E. A., Bakshi, N., & Khalid, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585761 · Cited by 16
Erre, G. L., Sebastiani, M., Manfredi, A., Gerratana, E., Atzeni, F., Passiu, G., & Mangoni, A. A. (2021) · Drugs in Context · doi:10.7573/dic.2020-8-6 · Cited by 16
Goos, T., Sadeleer, L. D., Yserbyt, J., Verleden, G. M., Vermant, M., Verleden, S. E., & Wuyts, W. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061330 · Cited by 17
Komatsu, M., Yamamoto, H., Kitaguchi, Y., Kawakami, S., Matsushita, M., Uehara, T., Kinjo, T., Wada, Y., Ichiyama, T., Urushihata, K., et al. (2021) · Medicine · doi:10.1097/md.0000000000025322 · Cited by 16
Nasonov, E. L., Ananyeva, L. P., & Avdeev, S. N. (2022) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2022-1 · Cited by 16
Li, D.-Y., Liu, X., Huang, J.-Y., Hang, W.-L., Yu, G.-R., & Xu, Y. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241232561 · Cited by 15
Animal models in systemic sclerosis: an update
Bi, X., Mills, T., & Wu, M. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000967 · Cited by 15
Yin, Y., Liu, S., Liu, H., & Wu, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115403 · Cited by 15
Herman, D. D., Ghazipura, M., Barnes, H., Macrea, M. M., Knight, S. L., Silver, R. M., Montesi, S. B., Raghu, G., & Hossain, T. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202301-081oc · Cited by 16
Self-citationJiang, H., Zheng, B., Hu, G., Kuang, L., Zhou, T., Li, S., Chen, X., Li, C., Zhang, D., Zhang, J., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.100971 · Cited by 15
Biciuşcă, V., Roşu, A., Stan, S. I., Cioboată, R., Biciusca, T., Bălteanu, M. A., Florescu, C., Camen, G. C., Cîmpeanu, O. L., Bumbea, A. M., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14232674 · Cited by 15
Broens, B., Nossent, E. J., Meijboom, L. J., Zwezerijnen, G. J. C., Spierings, J., Vries-Bouwstra, J. K. D., van Laar, J. M., van der Laken, C. J., & Voskuyl, A. E. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03447-x · Cited by 15
Mısırcı, S., Ekin, A., Yağız, B., Coşkun, B. N., Başıbüyük, F., Birlik, A. M., Sarı, İ., Karaca, A. D., Koca, S. S., Çetin, G. Y., et al. (2025) · Clinical Rheumatology · doi:10.1007/s10067-025-07323-0 · Cited by 16
Allanore, Y., Vonk, M. C., Distler, O., Azuma, A., Mayes, M. D., James, A., KOHLBRENNER, V. M., Alves, M., Khanna, D., & Highland, K. B. (2025) · RMD Open · doi:10.1136/rmdopen-2024-005086 · Cited by 15
Self-citationThe pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.
Kinoshita, Y., Ishii, H., Nabeshima, K., & Watanabe, K. (2021) · PubMed · doi:10.14670/hh-18-289 · Cited by 16
Benad, M., Koschel, D., Herrmann, K., Wiefel, K., Kleymann, A., & Aringer, M. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/o5t1f7 · Cited by 15
Cottin, V., Larrieu, S., Boussel, L., Si-Mohamed, S. A., Bazin, F., Marque, S., Massol, J., Thivolet-Béjui, F., Chalabreysse, L., Maucort‐Boulch, D., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.699532 · Cited by 15
Suzuka, T., Kotani, T., Saito, T., Matsuda, S., Sato, T., & Takeuchi, T. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02915-6 · Cited by 15
Niitsu, T., Fukushima, K., Komukai, S., Takata, S., Abe, Y., Nii, T., Kuge, T., Iwakoshi, S., Shiroyama, T., Miyake, K., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002667 · Cited by 15
Schmid, U., Weber, B., Magnusson, M. O., & Freiwald, M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106369 · Cited by 15
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis
Sgalla, G., Comes, A., & Richeldi, L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1921143 · Cited by 16
Associations of interstitial lung disease subtype and CT pattern with lung function and survival
Kim, J. S., Pugashetti, J. V., Ma, S., Huang, Y., Podolanczuk, A. J., Lynch, D. A., Oh, A. S., Mychaleckyj, J. C., Manichaikul, A. W., Rich, S. S., et al. (2025) · Thorax · doi:10.1136/thorax-2024-222149 · Cited by 15
Self-citationSystemic sclerosis: pathogenic mechanisms and their implications for treatment
Lescoat, A., Lecureur, V., Gudjonsson, J. E., & Khanna, D. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-025-01065-6 · Cited by 14
Lee, J. H., Jang, J. H., Lee, S., & Her, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412126 · Cited by 16
Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases
Hoffmann, T., Oelzner, P., Busch, M., Franz, M., Teichgräber, U. K.-M., Kroegel, C., Schulze, P. C., Wolf, G., & Pfeil, A. (2021) · Diagnostics · doi:10.3390/diagnostics12010067 · Cited by 14
Rankine, L. J., Lu, J., Wang, Z., Kelsey, C. R., Marks, L. B., Das, S. K., & Driehuys, B. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.02.049 · Cited by 14
Chaudhuri, N., Azuma, A., Sroka, K., Erhardt, E. M., Ritter, I., & Harari, S. A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03023-4 · Cited by 15
Self-citationThe Management of Interstitial Lung Disease in the ICU: A Comprehensive Review
Dhanani, Z., & Gupta, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226657 · Cited by 15
Zinellu, A., & Mangoni, A. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1442913 · Cited by 14
Yan, Q., Bruni, C., Garaiman, A., Mihai, C., Jordan, S., Becker, M. O., Elhaï, M., Dobrota, R. D., Petelytska, L., Henes, J. C., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.01.014 · Cited by 14
Self-citationQiu, Y., & Ye, W. (2025) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_132_25 · Cited by 14
Patient and Physician Perspectives on Systemic Sclerosis–Associated Interstitial Lung Disease
Cheema, T. J., Young, M., Rabold, E., Barbieri, A. N., Baldwin, N., & Steen, V. D. (2020) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.1177/1179548420913281 · Cited by 14
Takizawa, A., Kamita, M., Kondoh, Y., Bando, M., Kuwana, M., & Inoue, Y. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1860920 · Cited by 14
Self-citationInoue, Y., Suda, T., Kitamura, H., Okamoto, M., Azuma, A., Inase, N., Kuwana, M., Makino, S., Nishioka, Y., Ogura, T., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106574 · Cited by 14
Self-citationManagement of patients with fibrosing interstitial lung diseases
Morrow, L. E., Hilleman, D. E., & Malesker, M. A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab375 · Cited by 14
Karampitsakos, Τ., Kalogeropoulou, C. P., Tzilas, V., Παπαϊωάννου, Ο., Kazantzi, A., Koukaki, E., Katsaras, M., Bouros, E., Tsiri, P., Tsirikos, G., et al. (2021) · Respiration · doi:10.1159/000519215 · Cited by 14
Current perspective of progressive-fibrosing interstitial lung disease
Kishaba, T. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.03.004 · Cited by 14
Treatment approach to connective tissue disease-associated interstitial lung disease
Wilson, T. M., Solomon, J. J., & Demoruelle, M. K. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102245 · Cited by 15
Lu, M., Gong, L., Huang, C., Ye, M., Wang, H., Liu, Y., & Liu, D. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s391146 · Cited by 14
Diagnosing lung involvement in inflammatory rheumatic diseases—Where do we currently stand?
Hoffmann, T., Oelzner, P., Teichgräber, U. K.-M., Franz, M., Gaßler, N., Kroegel, C., Wolf, G., & Pfeil, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1101448 · Cited by 14
Karakontaki, F., Panselinas, E., Polychronopoulos, V., & Tzioufas, A. G. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102742 · Cited by 14
The role of pirfenidone in the treatment of interstitial pneumonia with autoimmune features
Chen, T., Li, Q., Zhang, Y., Yin, C., Weng, D., Zhou, Y., Hu, Y., Shi, J., Chen, Y., Ye, S., et al. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/off5n7 · Cited by 14
Pulmonary fibrosis in COVID-19: mechanisms, consequences and targets
O’Reilly, S. (2023) · QJM · doi:10.1093/qjmed/hcad092 · Cited by 13
Karampitsakos, Τ., Sampsonas, F., Herazo‐Maya, J. D., & Τzouvelekis, Α. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000977 · Cited by 13
Treatable Traits in Systemic Sclerosis
Amati, F., Bongiovanni, G., Tonutti, A., Motta, F., Stainer, A., Mangiameli, G., Aliberti, S., Selmi, C. F., & Santis, M. D. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08969-x · Cited by 13
Efficacy and limitations of repurposed drugs and vaccines for COVID-19
Murmu, N., Sarkar, M., Dey, S., Manna, R., Roy, S., Mondal, T., Halder, S., Bhattacharjee, N., Dash, S. K., & Giri, B. (2023) · Journal of Medicine Surgery and Public Health · doi:10.1016/j.glmedi.2023.100041 · Cited by 13
Quantifying the Need for Specialist Palliative Care Management in Patients With Systemic Sclerosis
Ross, L., McDonald, J. C., Hansen, D., Fairley, J. L., Wicks, C., Proudman, S., Walker, J. G., Sahhar, J., Ngian, G., Host, L., et al. (2024) · Arthritis Care & Research · doi:10.1002/acr.25325 · Cited by 13
Patient-centered care in pulmonary fibrosis: access, anticipate, and act
Hofman, D. E., Magrì, T., Moor, C. C., Richeldi, L., Wijsenbeek, M. S., & Waseda, Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02997-7 · Cited by 14
Characterization of Incident Interstitial Lung Disease in Late Systemic Sclerosis
Hoa, S. A.-T., Berger, C., Lahmek, N., LARCHÉ, M. J., Osman, M. S., Choi, M. Y., Pope, J. E., Thorne, C., & Hudson, M. (2024) · Arthritis & Rheumatology · doi:10.1002/art.43051 · Cited by 13
Merkt, W., Röhrich, M., Mavriopoulou, E., Stütz, A. N., Distler, J. H. W., Schmitt, A., Polke, M., Heußel, C. P., Schmitt, M. W., & Lorenz, H. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00159-6 · Cited by 14
Kondoh, Y., Fujii, T., Inoue, Y., & Atsumi, T. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103900 · Cited by 13
Metabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics
Zhou, Z., Wang, Y., Yan, D.-M., Fang, J.-H., Xiao, X.-R., Zhang, T., Cheng, Y., Xu, K.-P., & Li, F. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.113045 · Cited by 13
Yılmaz, D. D., Börekçi, Ş., & Müsellim, B. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05785-6 · Cited by 13
SSC-ILD mouse model induced by osmotic minipump delivered bleomycin: effect of Nintedanib
Ravanetti, F., Ferrini, E., Ragionieri, L., Khalajzeyqami, Z., Nicastro, M., Ridwan, Y. R., KleinJan, A., Villetti, G., Grandi, A., & Stellari, F. F. (2021) · Scientific Reports · doi:10.1038/s41598-021-97728-z · Cited by 13
Gernert, M., Tony, H., Fröhlich, M., Schwaneck, E. C., & Schmalzing, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.817893 · Cited by 13
Bruni, C., Heidenreich, S., Duenas, A., Hoffmann‐Vold, A., Gabrielli, A., Allanore, Y., Chatelus, E., Distler, J. H. W., HACHULLA, E., Hsu, V. M., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac126 · Cited by 13
Self-citationIL-33/Regulatory T-Cell Axis Suppresses Skin Fibrosis
Cheon, S. S. Y., Park, J. H., Ameri, A. H., Lee, R. T., Nazarian, R. M., & Demehri, S. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.03.009 · Cited by 13
Cheng, H., Yu, Z., Yan, C., Yang, H.-D., Gao, C., & Wen, H. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s373387 · Cited by 13
Nagy, T., Tóth, N. M., Palmer, E., Polivka, L., Csoma, B., Nagy, A., Eszes, N., Vincze, K., Bárczi, E., Bohács, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092129 · Cited by 13
Piotrowski, W. J., Martusewicz-Boros, M. M., Białas, A. J., Barczyk, A., Batko, B. P., Błasińska, K., Boros, P. W., Górska, K., Grzanka, P., Jassem, E., et al. (2022) · Advances in respiratory medicine · doi:10.3390/arm90050052 · Cited by 13
Shao, G., Hawle, P., Akbari, K., Horner, A., Hintenberger, R., Kaiser, B., Lamprecht, B., & Lang, D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1043720 · Cited by 13
Volkmann, E. R., Wilhalme, H. M., Assassi, S., Kim, G. H. J., Goldin, J. G., Kuwana, M., Tashkin, D. P., & Roth, M. D. (2023) · ACR Open Rheumatology · doi:10.1002/acr2.11598 · Cited by 13
Self-citationKolb, M. R. J., Flaherty, K. R., Silva, R. S., Prasse, A., Vancheri, C., Mueller, H., Sroka, K., Wells, A. U., & on behalf of the INBUILD trial investigators (2023) · Advances in Therapy · doi:10.1007/s12325-023-02668-x · Cited by 13
Distler, O., Allanore, Y., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Pope, J. E., Atsumi, T., Bečvář, R., Czirják, L., HACHULLA, E., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00238-2 · Cited by 13
Self-citationInterstitial Lung Disease Associated with Systemic Sclerosis
Mismetti, V., Si-Mohamed, S. A., & Cottin, V. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1786698 · Cited by 14
Wada, D. T., de Almeida, F. A., Moraes, D. A., Dias, J. B. E., Martínez, J. A. B., Oliveira, M. C., & Santos, M. K. (2019) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001242 · Cited by 13
Drugs in phase I and phase II clinical trials for systemic sclerosis
Chung, M. P., & Chung, L. S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1743973 · Cited by 14
Moll, S. A., Wiertz, I. A., Vorselaars, A. D. M., Zanen, P., Ruven, H. J. T., van Moorsel, C. H. M., & Grutters, J. C. (2020) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0165 · Cited by 13
Carvalho, A. R., Guimarães, A. R. M., Sztajnbok, F., Rodrigues, R. S., Silva, B. R. A., Lopes, A. J., Zin, W. A., Almeida, I., & França, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.577739 · Cited by 13
Ferlito, A., Campochiaro, C., Tomelleri, A., Dagna, L., & Luca, G. D. D. (2022) · Journal of Scleroderma and Related Disorders · doi:10.1177/23971983221083772 · Cited by 13
Allanore, Y., Khanna, D., Smith, V. M., Aringer, M., Hoffmann‐Vold, A., Kuwana, M., Merkel, P. A., Stock, C., Sambevski, S., Denton, C. P., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead280 · Cited by 12
Self-citationSevilla, J. P. H., Memon, A., & Hinchcliff, M. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03090-y · Cited by 13
Kato, M., Sasaki, S., Mori, W., Kohmaru, M., Akimoto, T., Hayakawa, E., Soma, S., Arai, Y., Matsubara, N. S., Nakazawa, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39101-w · Cited by 13
Nintedanib Plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis
Ikeda, S., Ogura, T., Kato, T., Kenmotsu, H., Agemi, Y., Tokito, T., Ito, K., Isomoto, K., Takiguchi, Y., Yoneshima, Y., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202311-941oc · Cited by 13
Developmental drugs for sarcoidosis
Obi, O. N., Saketkoo, L. A., Maier, L. A., & Baughman, R. P. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103179 · Cited by 13
Enomoto, N. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.03.006 · Cited by 12
Hannah, J. R., Rodziewicz, M., Mehta, P., Heenan, K.-M., Ball, E., Barratt, S. L., Carty, S., Conway, R. P., Cotton, C. V., Cox, S. J., et al. (2024) · Rheumatology Advances in Practice · doi:10.1093/rap/rkae056 · Cited by 12
Therapeutic strategies for primary heart involvement in systemic sclerosis
Batani, V., Dagna, L., & Luca, G. D. D. (2024) · Rheumatology and Immunology Research · doi:10.1515/rir-2024-0010 · Cited by 12
Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?
Bączek, K., & Piotrowski, W. J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1445923 · Cited by 12
Saavedra, A. A., Mueller, K. T., Kowalski, E., Qian, G., Bade, K. J., Vanni, K. M. M., McDermott, G. C., & Sparks, J. A. (2024) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-024-00217-3 · Cited by 12
Aggarwal, R., Oddis, C. V., Sullivan, D. I., Moghadam‐Kia, S., Saygın, D., Kass, D. J., Koontz, D. C., Li, P., Conoscenti, C., Olson, A. L., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03314-0 · Cited by 13
Grafanaki, K., Maniatis, A., Sotiropoulou, V., Pasmatzi, E., & Τzouvelekis, Α. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178394 · Cited by 13
Metadata
- Authors
- Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., Clerisme-Beaty, E., Stowasser, S., Tetzlaff, K., Kuwana, M., & Maher, T. M.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-27
- Volume
- 380
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945521814
- Cited by
- 1,647
- References
- 36
- Citations by year
- 2026: 139 · 2025: 203 · 2024: 215 · 2023: 231 · 2022: 243 · 2021: 299 · 2020: 247 · 2019: 68
- FWCI
- 157.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tyrosine kinase inhibitors, antifibrotic therapy, forced vital capacity decline, pulmonary fibrosis, diffuse cutaneous systemic sclerosis, skin involvement, quality of life, diarrhea, adverse events, mycophenolate, modified Rodnan skin score, St George's Respiratory Questionnaire
- MeSH terms
- Administration, Oral, Adult, Diarrhea, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Scleroderma, Systemic, Vital Capacity, Lung Diseases, Interstitial, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
